Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
21.92
-0.56 (-2.49%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Bicara Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Bicara Therapeutics stock have an average target of 28, with a low estimate of 16 and a high estimate of 42. The average target predicts an increase of 27.74% from the current stock price of 21.92.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Bicara Therapeutics stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 3 | 3 |
| Buy | 3 | 3 | 4 | 4 | 3 | 3 |
| Hold | 1 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 8 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $14 → $16 | Hold | Maintains | $14 → $16 | -27.01% | Mar 31, 2026 |
| Wedbush | Wedbush | Buy Reiterates $30 | Buy | Reiterates | $30 | +36.86% | Mar 31, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $11 → $16 | Hold | Maintains | $11 → $16 | -27.01% | Mar 31, 2026 |
| Citizens | Citizens | Buy Reiterates $31 | Buy | Reiterates | $31 | +41.42% | Mar 31, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | +91.61% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.71
from -2.52
EPS Next Year
-3.01
from -2.71
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.43 | -2.24 | ||||||
| Avg | -2.71 | -3.01 | ||||||
| Low | -2.80 | -4.05 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.